Intuitive Surgical stock gains 1.73 percent on Zacks Buy rank
π Intuitive Surgical stock gained 1.73% to trade at $411.78 on October 7, 2026, following a Zacks Buy rank upgrade.
π° Second-quarter revenue reached $2.89 billion, marking an 18.4% year-over-year increase driven by procedure volume growth.
π¬ Worldwide procedures grew 16% year over year in Q2 2026, reinforcing demand for the da Vinci and Ion surgical systems.
π― Analyst consensus shows a Buy rating with an average 12-month price target of $477.21, suggesting 15.89% upside potential.
π The company is scheduled to release Q3 earnings on October 20, 2026, providing the next major data checkpoint.
π Intuitive Surgical holds a market capitalization of $145.5 billion with a 52-week trading range between $328.57 and $603.88.
Bullish Signals
- Intuitive Surgical reported second-quarter revenue of $2.89 billion, a significant 18.4% year-over-year increase driven by strong procedure volume.
- Worldwide procedures grew 16% year over year in Q2 2026, validating the recurring revenue model for its da Vinci and Ion surgical systems.
- Analyst consensus from Investing.com includes a Buy rating with an average 12-month price target of $477.21, indicating 15.89% upside from current levels.
- The stock received a Zacks Rank No. 2 Buy classification on October 6, 2026, reflecting positive sentiment regarding the medical-instruments industry outlook.
Risk Factors
- Intuitive Surgical shares are trading 31.81% below their 52-week high of $603.88, suggesting a potential valuation gap despite recent revenue growth.
- The stock price remains well below analyst expectations as the market awaits confirmation that Q3 results will sustain the current growth trajectory.
Full Analysis
Intuitive Surgical (ISRG) shares rose 1.73% to $411.78 on October 7, 2026, following a Zacks Rank No. 2 Buy rating assigned on October 6. The medical device giant reported robust second-quarter revenue of $2.89 billion, representing an 18.4% year-over-year increase driven by growth in worldwide procedures.
Analyst consensus remains bullish with Investing.com citing a Buy rating from 32 analysts and an average 12-month price target of $477.21, implying approximately 15.9% upside from current levels. The high target reaches $685.00 while the low sits at $324.00, reflecting divergent expectations within the sector.
Company fundamentals highlight a strong operational trajectory with worldwide procedures expanding 16% year over year in Q2 2026. This growth supports recurring demand for its da Vinci surgical systems and Ion endoluminal system, positioning the company well ahead of its next earnings release scheduled for October 20, 2026.
The stock currently trades at a market capitalization of $145.5 billion, sitting 31.81% below its 52-week high of $603.88. Investors are watching to see if the reported revenue expansion and procedure growth can bridge the valuation gap before the upcoming quarterly report.